Advanced Cell Technology, Inc. (OTCBB:ACTC – News) today announced that it has completed the acquisition of all of the outstanding capital stock of Mytogen, Inc. In May 2007, the company announced that it had entered into a letter of intent to acquire Mytogen, Inc. and its Myoblast Program for the treatment of heart failure.
Get the full story...
Advanced Cell Technology, Inc. (OTCBB:ACTC – News) announced today that it completed a private placement with institutional and other accredited investors resulting in gross proceeds of $10 million.
Get the full story...
Advanced Cell Technology, Inc. is proud to announce that Dr. Robert Lanza, the company’s Vice President of Research and Scientific Development, has been recognized for his research and contributions to stem cell science and technology in the current issue of PharmaVOICE (cover story July/August issue).
Get the full story...
Advanced Cell Applauds $3 Billion Stem Cell Research Program, Proposition 71, Upheld Monday By A California Appeals Court
Read the full story
Advanced Cell Technology, Inc. announced today that it has acquired the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer (SCNT), parthenogenesis, and other related technologies.
Read the full story
Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University
Read the full story
Highly Regarded Merchant Bank to Assist in Creation of ACTC Development Partnerships with Major Biotechnology Research Organizations Worldwide
Read the full story
NIH Grant Supports Collaboration to Develop Stem Cell Science and Novel Therapies
Read the full story
Board of Directors Vote Unanimously to Expand CEO's Role with Appointment as Chairman
Read the full story
